Pulmonary and Critical Care Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
J Allergy Clin Immunol. 2010 Feb;125(2):295-302; quiz 303-4. doi: 10.1016/j.jaci.2009.12.014.
There is a large amount of interindividual variability in both therapeutic and adverse responses to asthma therapies. Genetic variability can account for 50% to 60% of this variability. Pharmacogenomics holds out the promise of allowing clinicians to prospectively choose therapies that have the greatest likelihood to be effective for individual patients and to avoid those that might have a high likelihood of producing adverse effects. In this article we review the principles of pharmacogenomic investigation. We explore the data developed from the early pharmacogenomic studies with the most common asthma therapies. Furthermore, we explore the potential use of pharmacogenomics, as well as caveats in interpreting such information.
在哮喘治疗的疗效和不良反应方面，个体间存在很大的差异。遗传变异性可以解释这种差异的 50%到 60%。药物基因组学有望让临床医生有前瞻性地选择最有可能对个体患者有效的治疗方法，并避免那些可能产生不良反应的治疗方法。本文综述了药物基因组学研究的原理。我们探讨了早期药物基因组学研究中最常见的哮喘治疗方法所产生的数据。此外，我们还探讨了药物基因组学的潜在应用以及解释这些信息时的注意事项。
